이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

뇌전이로 방사선 치료를 받는 환자의 신경심리학적 변화

2026년 11월 10일 업데이트: National Cancer Institute (NCI)

뇌전이로 방사선 치료를 받는 환자의 신경심리학적 결과 측정 및 예후와의 관계를 평가하기 위한 파일럿 연구

Background:

  • There are no standardized sets of tests to measure changes in neuropsychological functioning in patients treated for brain metastasis (cancer that has spread beyond the original site to the brain).
  • Neuropsychological function has an important effect on quality of life and should be included when determining treatment options.

Objectives:

  • To find out if there is a change in patients cognitive (thinking) and daily functioning after standard radiation treatment for brain metastasis that can be measured with tests.
  • To see if any changes on these tests are related to patients response to radiation therapy.

Eligibility:

- Patients 18 years of age or older who have cancer that has spread to the brain.

Design:

  • Patients receive a 2-week course of radiation therapy to the brain, given daily 5 days a week. Some patients may require stereotactic radiosurgery (an additional boost of radiation therapy to specific sites of brain metastasis).
  • Patients have the following evaluations before and after treatment to determine changes in cognition and functioning:
  • Neuropsychological testing to measure cognitive (thinking) abilities like memory, attention, processing speed, and reading, and fine motor skills.
  • Questionnaires to assess quality of life and daily living skills.
  • Patients have MRI scans and blood and urine tests.
  • At the completion of radiation treatment, patients return to the clinic for follow-up visits at 1, 2, 4, 6, 9 and 12 months for blood and urine tests, physical examination, MRI of the brain, neuropsychological testing and assessments of quality of life and daily living skills.

연구 개요

상태

완전한

정황

상세 설명

Background:

  • Metastatic brain tumors occur more frequently than primary brain tumors and occur in approximately 25 percent of patients who die of cancer each year.
  • The Radiation Therapy Oncology Group (RTOG) developed three prognostic classes using a recursive partitioning analysis (RPA) of a large database. These classes are based on Karnofsky Performance Status (KPS), age and disease status.
  • The RTOG RPA classes do not include neuropsychological function as a measure of outcome.
  • There is no consensus of standardization of test selection to measure changes in neuropsychological functioning in this patient population.
  • Neuropsychological function has an important effect on quality of life and should be included when determining prognosis and treatment options for patients.
  • Neuropsychological functioning is important when determining the effects of treatments and for measuring outcomes in clinical trials.

Objectives:

  • To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases.
  • To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases.

Eligibility:

  • Patients aged 18 years and older.
  • Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.
  • The patient must communicate in English in order to complete the neuropsychological evaluations.

Design:

  • This is a longitudinal study that will administer serial neuropsychological assessments to patients with brain metastases who receive radiation therapy.
  • Patients will undergo a battery of neuropsychological tests prior to radiotherapy (WBRT or WBRT followed by SRS), 2 weeks after completion of radiation therapy, then every 3 months for up to 12 months.
  • The test battery will involve approximately 40 minutes of direct cognitive testing and 15 minutes of questionnaires.

There will be three cohorts of 20 patients each for a total of 60 patients. The three cohorts will be made up of differing histologies and will be sorted on the basis of their RTOG RPA Class.

연구 유형

관찰

등록 (실제)

35

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Primary clinical

설명

-INCLUSION CRITERIA:

  1. Patients must be 18 years of age or older.

  2. Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.

    • Cohort 1 (N=20): KPS greater than 70; Age less than or equal to 65; controlled primary tumor and no extracranial metastases.
    • Cohort 2 (N=20): KPS greater than 70 and at least one of the following: age greater than 65, uncontrolled or synchronous primary disease, or extracranial metastases
    • Cohort 3 (N=20): KPS less than 70
  3. Patient must have a primary medical or surgical oncologist in the community or at NCI who is willing to collaborate with the ROB staff in the clinical management of the patient.

  4. All patients must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study BEFORE any of the protocol related studies are preformed (this does not include routine laboratory tests or imaging studies required to establish eligibility).

  5. Subjects of childbearing or child- fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study.

EXCLUSION CRITERIA:

  1. Cognitively impaired patients who cannot give informed consent, including patients assigned a power of attorney for medical decisions.

  2. Inability to communicate in the English language.

  3. Pre- existing or active psychiatric or neurologic impairments, not caused by the brain metastasis, which, in the opinion of the investigators, will interfere with the proper administration or completion of the protocol.

  4. Prior Therapy

    • Patients must not have been treated for a previous brain metastasis.
    • Patients must not have had previous cranial radiation.
    • Patients must not undergo treatment with an investigational drug for the primary disease within 7 days of baseline neuropsychological testing.
    • Patients must not receive systemic therapy within 7 days prior to baseline neuropsychological testing.
    • Patients who have had surgery for their current brain metastasis must wait at least 7 days before baseline neuropsychological testing.
  5. Concurrent Therapy

    • Treatment of primary malignancy with systemic therapy (chemotherapy or biologic agents) cannot be delivered concurrently with the treatment of the intracranial disease. However, treatment of the primary site with local therapy, either surgery or radiotherapy, can be performed concurrently with the treatment of the intracranial disease.
    • Patients receiving glucocorticoids should be tapered to the lowest possible dose, or stopped altogether, by the treating physician. If glucocorticoid dose is adjusted or given for the first time, the patient must remain on stable dose of glucocorticoids for at least 24 hours prior to initial neurocognitive testing, CT and MR imaging.
  6. Patients needing emergent radiation therapy for their brain metastases will be excluded.

  7. Patients must not have evidence of leptomeningeal metastases.

  8. Patients must not be HIV positive.

  9. Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations.

  10. Pregnant or breast-feeding females are excluded because of the potential mutagenic effects on a developing fetus or newborn.

  11. Clinically significant unrelated systemic illness which in the judgment of the Principal or Associate Investigator would compromise the patient s ability to tolerate this therapy or are likely to interfere with the study procedures or results.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
1/Cohort 1

KPS>70; Age =65; controlled primary tumor and no extracranial metastases

2/Cohort 2

KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases

3/Cohort 3

KPS<70

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Neuropsychological function
기간: Completion of study

To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases

Completion of study
Test scores for: Hopkins Vrbl Learning Test recall; WAIS-III Digit Span; the WAIS-III Symbol Search; the Ruff 2 & 7 Selective Attn. The Trailmaking Tst Part B speed z-score; and the Grooved Pegboard Test dominant hand z-score
기간: Completion of study

To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases

Completion of study

2차 결과 측정

결과 측정
측정값 설명
기간
Strengths and weaknesses in neuropsychological functioning
기간: completion of study

To examine the strengths and weaknesses in neuropsychological functioning of patients with brain metastases after radiation therapy

completion of study
RTOG RPA classification
기간: completion of study

To examine the relationship between the RTOG RPA classification for brain metastasis survival and baseline neuropsychological functioning

completion of study
North American Adult Reading Test-Short Form (NART-35), Hopkins Verbal Learning Test (HVLT), WAIS-III Digit Span subtest, WAIS-III Symbol Search subtest, Ruff 2 and 7 Selective Attention Test
기간: completion of study

To further examine whether other measures from the following battery detect significant change in neuropsychological function or predict prognosis in this patient population

completion of study
Neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence
기간: completion of study

To investigate the relationship between neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence

completion of study
Neuropsychological functioning
기간: completion of study

To explore the neuropsychological functioning of patients with brain metastases treated with different therapies (e.g. chemotherapy, corticosteroids, complete surgical resection)

completion of study
neuron specific enolase (NSE), S100B, MMPs and VEGF
기간: completion of study

To investigate the role of biomarkers, including neuron specific enolase (NSE), S100B, MMPs and VEGF as potential markers of brain injury and disease progression in the serum, plasma and urine of patients with brain metastases

completion of study
Baseline neuropsychological data
기간: completion of study

To gather baseline neuropsychological data on patients with brain metastases for use as a reference in the development of new clinical trials involving this patient population in the ROB

completion of study

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: DeeDee K Smart, M.D., National Cancer Institute (NCI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2009년 4월 17일

연구 등록 날짜

최초 제출

2011년 9월 30일

QC 기준을 충족하는 최초 제출

2011년 9월 30일

처음 게시됨 (추정된)

2011년 10월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 7월 14일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD 공유 기간

Clinical data available during the study and indefinitely.

IPD 공유 액세스 기준

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다